Merck (MRK) Long-Term Deferred Tax (2010 - 2023)

Merck has disclosed Long-Term Deferred Tax across 14 years of filings, most recently posting $10.2 billion for Q2 2023.

• In Q2 2023, Long-Term Deferred Tax fell 7.15% year-over-year to $10.2 billion; the TTM figure through Jun 2023 stood at $10.2 billion (down 7.15% YoY), while the FY2022 annual figure was $9.5 billion, down 17.73% from the prior year.
• Long-Term Deferred Tax eased to $10.2 billion in Q2 2023, from $10.3 billion in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for MRK reached as high as $11.6 billion in Q4 2021 and fell as low as $6.8 billion in Q4 2019.
• The 5-year median for Long-Term Deferred Tax is $9.7 billion (2020), against an average of $9.6 billion.
• Annual changes were most pronounced in 2020 — Long-Term Deferred Tax decreased 19.01% — and 2021, when it surged 48.7%.
• A 5-year view of Long-Term Deferred Tax shows it stood at $6.8 billion in 2019, then soared by 45.93% to $9.9 billion in 2020, then climbed by 17.21% to $11.6 billion in 2021, then decreased by 17.73% to $9.5 billion in 2022, then advanced by 6.92% to $10.2 billion in 2023.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $10.2 billion, $10.3 billion, and $9.5 billion for Q2 2023, Q1 2023, and Q4 2022 respectively.